Search Results
Aug 06, 2026, 06:00 ET EPAM Reports Results for Second Quarter 2026
strategy," said Balazs Fejes, CEO & President, EPAM. "As we continue to expand our strategic partnerships and leverage our 30+ years of engineering DNA to build the next generation forward-deployed engineering organization, our conviction in the strategy, the team and our commercial transformation is
More news about: EPAM Systems, Inc.
Aug 06, 2026, 05:14 ET Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance
priorities in immuno-oncology research.Pidnarulex (CX-5461) is Senhwa's first-in-class investigational agent designed to induce DNA replication stress and DNA damage responses in cancer cells. Emerging research suggests that these mechanisms may not only directly impair tumor-cell survival but
More news about: Senhwa Biosciences, Inc.
Aug 05, 2026, 16:02 ET GRAIL Reports Second Quarter 2026 Financial Results
Galleri® The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer, to help screen for some of the deadliest cancers that don't have recommended
More news about: GRAIL, Inc.
Aug 05, 2026, 11:01 ET Cold Spring Harbor Laboratory and Northwell Health lead international cohort of researchers to develop more than 150 next-generation cancer treatment models
tissue material from original tumors along with complete clinical information linked to each sample. Additionally, advanced molecular profiles, such as DNA and RNA sequences, and transcriptomic and epigenetic data are available, allowing scientists to analyze the organoids for a more comprehensive picture
More news about: Cold Spring Harbor Laboratory
Aug 05, 2026, 08:47 ET angela adams Announces Next Generation of Ownership to Secure Legacy and Future Growth
landscape. The decision to transition ownership to the Hanly family was driven by a shared vision: ensuring the company remains true to its authentic DNA while continuing to grow as a leader in artisanal home design."It was important to us that the business remain in Maine and be stewarded by a
More news about: angela adams
Aug 05, 2026, 08:46 ET Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
EsoGuard® Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology (ACG) screening criteria."Securing this coverage policy
More news about: Lucid Diagnostics
Aug 05, 2026, 08:33 ET The Assessment Company® Releases Merit-Based Hiring Guide for Private Employers
and development decisions. The company provides PXT Select and related workplace assessment solutions as an Authorized Wiley Partner. Its Occupational DNA® process connects job requirements with consistent assessment and interview evidence. The Assessment Company® does not provide technical skills testing
More news about: The Assessment Company®
Aug 05, 2026, 08:17 ET Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
cancer derived plasma DNA from healthy DNA when the two are mixed is problematic as they are chemically similar. As the cancer DNA may make up 1% or less of the total DNA, it is extremely problematic. "Our manuscript describes a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our work
More news about: VolitionRx Limited
Aug 04, 2026, 16:05 ET INOVIO to Report Second Quarter Financial Results on August 12, 2026
biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting
More news about: INOVIO Pharmaceuticals, Inc.
Aug 04, 2026, 10:00 ET New England Biolab® launches Monarch® Mag Cell-free RNA (cfRNA) Extraction Kit to enable total cfRNA isolation from biofluids
consistent recovery of low abundance cfRNA and removal of DNA contamination so they can assess this valuable but under-investigated analyte."The kit addresses two persistent technical challenges in total circulating RNA extraction: DNA carryover and loss of small RNAs. Chaotropic salt-based chemistry,
More news about: New England Biolabs, Inc.
Aug 04, 2026, 08:51 ET Creatio's Quarterly Bookings Reach 255% of Prior-Year Results as Enterprises Adopt AI at Scale
customers in over 100 countries and automates tens of millions of workflows daily. Genuine care for our clients and partners is at the heart of our DNA. Learn more at
More news about: Creatio
Aug 04, 2026, 08:30 ET Lucid Diagnostics to Participate in Upcoming Investor Conferences
EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its
More news about: Lucid Diagnostics
Aug 04, 2026, 07:30 ET MDA SPACE AWARDED $474 MILLION TO EXPAND THE TELESAT LIGHTSPEED LEO CONSTELLATION
vision into an achievable mission — bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Aug 04, 2026, 03:00 ET Haut.AI Launches AI-Powered Clinical Studies Software for Large-Scale Skin Studies Across Clinic, Hybrid, and At-Home Environments
TruDiagnostic. "Haut.AI's Clinical Studies Software gave us standardized, image-derived measures of facial aging traits that we could pair directly with our DNA methylation data. That combination let us treat visible aging as a quantitative trait alongside our biological measurements, instead of relying on subjective
More news about: Haut.AI
Aug 03, 2026, 16:10 ET Alexandria Real Estate Equities, Inc. Reports 2Q26 and 1H26 Net (Loss) Income per Share - Diluted of $(0.43) and $1.68, respectively, and 2Q26 and 1H26 FFO per Share - Diluted, as Adjusted, of $1.73 and $3.46, respectively
Alexandria®, Lighthouse Design® logo, Building the Future of Life-Changing Innovation®, That's What's in Our DNA®, Megacampus™, At the Vanguard and Heart of the Life Science Ecosystem™, Alexandria Center®, Alexandria Technology Square®,
More news about: Alexandria Real Estate Equities, Inc.
Aug 03, 2026, 12:00 ET Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
Genomics for All, a clinical-grade whole genome sequencing product priced at $599. The offering sequences all 6.4 billion base pairs of an individual's DNA and delivers AI-interpreted results through the HLI app, with no clinic visit required.
More news about: Human Longevity, Inc.
Aug 03, 2026, 10:01 ET Green Science Alliance Developed Carbon Quantum Dot type Pest Repellent from Organic Biomass Waste (Wood Waste, Plant Waste, Food Waste)
effect against insects. He suggests some reasons as followings. Ultra-small quantum dots can pass through insect cells and nuclear membranes to damage DNA, quantum dots emit light at wavelengths that insects dislike, or quantum dots also have photocatalytic properties, meaning that when exposed to sunlight,
More news about: Green Science Alliance Co., Ltd.
Aug 03, 2026, 09:00 ET STANLEY® Launches ALL BUILD. NO BULL., a Bold New Campaign Championing the Pros Who Keep It Real
Europe, Australia and New Zealand starting in August. All Build from Day One The all-work mentality has been part of STANLEY's DNA from the start. When the brand was founded in 1843, Founder Frederick Stanley saw the need for a brand that made tools shaped by the work, and workers
More news about: STANLEY
Aug 03, 2026, 08:00 ET FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that
More news about: Acurx Pharmaceuticals, Inc.
Aug 02, 2026, 14:34 ET HIZENERGY sa pridáva ku globálnej špičke - zaradenie do zoznamu BloombergNEF 1. úrovne
HEFEI, Čína, 2. augusta 2026 /PRNewswire/ – Dňa 31. júla 2026 zverejnil BloombergNEF (BNEF), popredný svetový inštitút pre výskum v oblasti energetiky, svoj zoznam výrobcov úložísk energie 1. úrovne na tretí štvrťrok 2026.
More news about: HIZENERGY
Jul 31, 2026, 13:31 ET Nabsys and Indiana University Collaborate to Advance Electronic Genome Mapping Applications in Hematologic Malignancies
determine how it may enhance existing cytogenetic research workflows.The OhmX™ Platform uses proprietary electronic detection to analyze ultra-long DNA molecules. By replacing complex and expensive optical systems with precision electronics, EGM enables a compact, cost-effective platform capable of delivering
More news about: Nabsys
Jul 31, 2026, 10:30 ET Animal Genetics Market worth $9.37 billion by 2031 - Exclusive Report by MarketsandMarkets™
and precision breeding, diagnostic centers are expanding their molecular testing capabilities using technologies such as PCR, SNP genotyping, NGS, and DNA sequencing to deliver accurate and high-throughput genetic analyses. Rising awareness of genetic disease prevention, growing outsourcing of genetic testing
More news about: MarketsandMarkets
Jul 31, 2026, 08:30 ET PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer
More news about: PAVmed Inc.
Jul 30, 2026, 16:05 ET Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jul 30, 2026, 10:35 ET Peer-Reviewed Study Validates First Blood Test for Early-Stage Breast Cancer Detection
decades, liquid biopsies have leaned on DNA-based blood tests — an approach that has struggled for breast cancer for a simple biological reason: early breast tumors shed only about a tenth of the DNA compared to other cancers, including colorectal. That is why DNA-based multi-cancer tests have shown low
More news about: Astrin Biosciences